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Results of clotting tests used to measure the effect of old and new antithrombotic drugs can be expressed in
different ways and this is considered as one of the sources of variability to explain the differences of results
obtained for the same patient plasma when tested in different laboratories. This is particularly important for patient
on vitamin K antagonists and led to the development of the international normalized ratio system of results
reporting in this setting. Although standardization of results expression for the tests meant to measure the
anticoagulant effect of new oral anticoagulants (NOA) is presently not perceived as an issue, it may become
crucially important at the time when test-specific cut off values will be available to help assessing the risk of
bleeding in individual patients who are on over-dosage. Effort should therefore be made to harmonize as much as
possible results obtained in different laboratories using the same method, but different reagents. This article is
aimed at discussing different options of results reporting of tests for NOA and their merits/pitfalls.Introduction
Although clinical trials for the new oral anticoagulants
(NOA) [1] demonstrated that they do not require dose-
adjustment by means of laboratory testing, the measure-
ment of their anticoagulant effect may be useful in many
circumstances including preoperative screening; patients
admitted to the emergency department because of
adverse events (hemorrhage or thrombosis); patients
with chronic renal insufficiency; patients taking other
drugs that are known or suspected to interact with the
NOA. In all these circumstances few tests may be re-
quired and according to recent recommendations they
are the prothrombin time (PT) test or the measurement
of the anti-factor Xa activity for rivaroxaban and the di-
lute thrombin time (dTT) or the ecarin clotting time
(ECT) for dabigatran [2,3]. The results of these tests
may be expressed in different ways and no specific rec-
ommendations have hitherto been issued. This article is
aimed at reviewing the most important results expres-
sion and their relevance for the laboratory measurement
of the anticoagulant effect of NOA.Correspondence: armando.tripodi@unimi.it
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Prothrombin time
Results for PT are commonly reported as (i) clotting times
(seconds); (ii) ratio of patient-to-normal clotting times [i.e.,
PT-ratio = (PTpatient/PTnormal)] or as (iii) international nor-
malized ratio (INR) [i.e., INR = (PTpatient/PTnormal)
ISI] where
the ISI is the international sensitivity index of the
thromboplastin used for testing and represents its re-
sponsiveness to the PT prolongation mediated by vita-
min K antagonists (VKA) relatively to the World
Health Organization (WHO) international standard for
thromboplastin [4]. The INR has been devised to
harmonize PT results across thromboplastins, but only
for patients on VKA. Hence, any other application
should be validated before use to see whether it is able
to minimize between-thromboplastin results. For ex-
ample, it was recently shown that the regular INR is
unable to minimize PT results for patients with chronic
liver disease [5]. However, the same authors showed
that the system could be reliably used also in this set-
ting provided that modification in the determination of
the ISI was introduced [5]. Similarly, other authors pro-
vided evidence that appropriate modifications of the ISI
makes the INR scale suitable to minimize the between-
thromboplastin differences of PT results for patients
with disseminated intravascular coagulation [6] or tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Tripodi Thrombosis Journal 2013, 11:9 Page 2 of 5
http://www.thrombosisjournal.com/content/11/1/9minimize between-reagent differences for coagulation
testing to detect lupus anticoagulants [7]. All the above
observations can be taken as evidence that the INR is a
system suitable to minimize between-reagent variability
of coagulation test results provided that specific sensi-
tivity indexes relatively to common standards are calcu-
lated for different clinical conditions.
Recently, it has been shown that PT results, expressed
as clotting times (seconds) or PT-ratio, for patients on
rivaroxaban vary according to the thromboplastin used
for testing [8]. More recently, this variability was quanti-
fied by measuring the PT for normal plasmas spiked
with known amounts of rivaroxaban to mimic plasmas
from patients on treatment [9]. The average PT-ratios
(patient-to-normal) for three plasmas at rivaroxaban
concentrations of 100, 300 or 700 ng mL−1 were 1.27, 1.76
or 2.67, respectively [9]. The between-thromboplastin vari-
ability calculated as the coefficient of variation (CV) of
results obtained with six commercial thromboplastins,
testing each of the above plasmas, amounted to 5.5%,
12.1% and 18.1% (average value, 14%) [9].The above men-
tioned variability was dramatically increased when results










































Figure 1 Calibration of thromboplastins to determine the Rivaroxaba
normal plasma were spiked with increasing amounts of rivaroxaban. Plasmas
common thromboplastin (referred as common standard). Prothrombin time (
standard on the vertical axis) and the best-fit line was drawn. The slope of the
can be taken as a measure of the responsiveness of the rivaroxaban-induced
standard. The Riva-SI can be used to convert PT results (seconds) into rivaroxa
following equation: Riva-PT-ratio = [PTpatient/PTnormal]
Riva-SI. This system of stand
variability of the PT for rivaroxaban-spiked plasmas (see text more details). The
definition the higher the Riva-SI the lower the responsiveness of the thrombo
represent the coefficient of variation of the slope estimation. The Riva-SI for th
change appreciably when Neoplastin Plus was used as the common standard39.0% (average value, 29.6%) [9]. These results tell us that
the between-thromboplastin variability of the PT-ratio for
plasmas containing rivaroxaban is relatively high and that
the regular INR is unable to minimize such variability as it
occurs for patient on VKA. Hence, the regular INR cannot
be used to express results for patients on rivaroxaban.
Subsequent studies showed that there may be an add-
itional expression of PT results suited to be applied in
patients on rivaroxaban [9]. It was hypothesized that the
responsiveness of the clotting time prolongation of
working thromboplastins induced by rivaroxaban could
be determined by testing plasmas added with increasing
amounts of rivaroxaban with the working and standard
thromboplastins. If the paired PTs (seconds), plotted on
a double-log scale, are linearly related, the slope of the
orthogonal regression line can be taken as an index of
the responsiveness of the working thromboplastin rela-
tively to the international standard (Figure 1). By defin-
ition, a slope value equal to the unity denotes that the
working thromboplastin possesses the same responsive-
ness to rivaroxaban as the standard thromboplastin.
Likewise, the greater the slope the lower the responsive-






a-SI=1.014 (1.0) Riva-SI=1.196 (1.0)
1.712 (1.4)
n sensitivity index (here referred as Riva-SI). Aliquots of a pooled
were then tested with five commercial thromboplastins and with a
PT) results (seconds) were then plotted on a double-log scale (common
line, estimated by the orthogonal regression analysis is the Riva-SI and
PT prolongation of the five thromboplastins relatively to the common
ban standardized PT ratio (here referred as Riva-PT-ratio) according to the
ardization was effective in minimizing the between-thromboplastin
Riva-SI relatively to the common standard is reported on each graph. By
plastin to the effect induced by rivaroxaban. The numbers in brackets
e common standard has been arbitrarily set at 1.00. Results did not
[9].
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recommended by WHO for the determination of the ISI
of thromboplastins used for patients on VKA [4]. The nu-
merical value of the slope, provisionally called rivaroxaban
sensitivity index (Riva-SI), can then be used to convert re-
sults of the PT (seconds) into a new scale, called




This system of standardization proved feasible [9] for
the following reasons. (i) Six thromboplastins testing
plasmas spiked with rivaroxaban yielded results that
were linearly related to those of a common thrombo-
plastin standard; (ii) the data points could be repre-
sented by a best-fit orthogonal regression line and (iii)
the slope of the line could be estimated with a high
degree of confidence with CV value (that is a measure of
the calibration precision) less than the required 3% [4]
(see Figure 1). The responsiveness to rivaroxaban was the
highest for Neoplastin Plus (Stago, Asnieres, France) and
Recombiplastin (Instrumentation Laboratory, Orangeburg,
NY) (i.e., Riva-SI close to unity) and the lowest for Innovin
(Siemens Health Care Diagnostics, Marburg, Germany)
(Riva-SI = 1.712) (see Figure 1). Interestingly, the respon-
siveness to rivaroxaban does not depend on the species
of the thromboplastin as shown by the evidence that
two human recombinant thromboplastins such as Re-
combiplastin and Innovin display similar responsiveness
to VKA, but completely different responsiveness to
rivaroxaban (see Figure 1).
In the second step of the study, the above system of
standardization was validated by testing three rivaroxaban-
spiked plasmas (that were different from those used for
the determination of the Riva-SI) [9]. The overall
between-thromboplastin variability of the PT results that
was on average 14.1% or 29.6% when results were ex-
pressed as PT-ratio or INR was reduced to a mere 2.1%
when results were expressed as Riva-PT-ratio [9]. These
results and conclusions were recently confirmed by
Harenberg et al. [10].
The Riva-PT-ratio although feasible should be further
investigated to address practical issues that have been
previously discussed in detail [9]. For instance, in the
model so far proposed normal plasmas spiked with in-
creased amounts of rivaroxaban have been used to deter-
mine the Riva-SI for the working thromboplastins.
These plasmas although representative do not necessar-
ily mirror the real situation of plasmas from patients
treated with rivaroxaban. This issue had already been
considered for the calibration of the INR in patients on
VKA and guidelines have been issued on preparation,certification and use of certified plasmas for ISI calibra-
tion and INR determination [11]. Further work is, there-
fore, needed to give specific details on the preparation,
certification, validation and use of rivaroxaban-spiked
plasmas. In this respect, some work has already been
carried out [12], but much remains to be done. Upon
further investigation and validation the Riva-PT-ratio
could be implemented in clinical laboratories. In prac-
tice, PT results for patients on rivaroxaban could be
converted into Riva-PT-ratios by using the above equa-
tion. The parameters needed are the PTnormal and the
Riva-SI value for the working thromboplastin. The first
may be calculated as the geometric mean PT value of
20 or more healthy subjects or as the clotting time of
the pooled normal plasma [4]. The second should be
determined by the manufacturers by testing with their
thromboplastins and with the international standard for
thromboplastin (available from WHO) a set of rivaroxaban-
spiked plasmas according to the described protocol [9].
This system of reporting does not require the use of
calibration plasmas in the local laboratories and would
reduce the cost incurred for patient management.
It was proposed that the results of the PT test for pa-
tients on rivaroxaban can also be reported as rivaroxaban-
equivalent concentrations [12]. This may be achieved by
testing in local laboratories the PT for a set of plasmas
spiked with known and increasing amounts of riva-
roxaban. The PT value (seconds) can then be plotted on a
linear scale versus the rivaroxaban concentrations and
used to construct local calibration curves. Patients clotting
times can be interpolated from these calibration curves
and the results converted directly into rivaroxaban-
equivalent concentrations. The validity of this system of
reporting rests on the assumption that the interaction be-
tween rivaroxaban and plasma does not vary in individual
patients, an assumption that, however, cannot be taken for
granted. For instance, it is reasonable to assume that cali-
bration curves prepared by different normal plasmas
spiked with the same amounts of rivaroxaban may yield
different slope and intercept. Hence, the drug con-
centrations derived thereafter for the same patient could
be different, depending on the curve used for the
interpolation. Furthermore, it should be realized that pa-
tients to be treated with rivaroxaban may have variable
baseline PT values and often different from the value of
the normal plasma used for spiking. This variability may
have unpredictable effect on results expression as drug
concentration-equivalent.
In conclusion, based on the present limited expe-
rience, I believe that PT results for patients on
rivaroxaban can be expressed as PT-ratio, possibly as
Riva-PT-ratio (if this system will be implemented), but
not as INR as this expression dramatically magnify the
between-thromboplastin variability.
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The assay is based on the capacity of rivaroxaban to
quench factor Xa activity added in excess to the test
plasma. The residual factor Xa activity that is inversely
proportional to the rivaroxaban activity is measured by
means of a specific synthetic substrate. The results are
expressed primarily in terms of optical density and sub-
sequently converted into rivaroxaban concentrations by
interpolation from a calibration curve prepared locally
by testing plasmas spiked with increasing concentrations
of rivaroxaban [13]. Although this expression of results
is the obvious solution, it should be realized that it
might not be an adequate system of standardization as
shown by the rather large inter-laboratory variability that
was observed in a multicenter survey of anti-factor Xa
methods for rivaroxaban [14]. In the survey, 21 labora-
tories were asked to measure rivaroxaban concentrations
in the same plasma using their local reagents. The re-
sultant calculated inter-laboratory CV value amounted
to 25%, despite the fact that local reagents for anti-factor
Xa determination were calibrated with the same set of
calibration plasmas [14]. On the other hand, the lesson
learnt from the attempt to standardize the anti-factor Xa
assay for low molecular weight heparins [15] tells us that
even in the setting of rivaroxaban, standardization across
reagents is far reaching. In practical terms this means
that any cut-off value, which will eventually be deter-
mined on the concentration of drug obtained with a spe-
cific anti-factor Xa method, cannot be easily generalized
to other reagents.
Dilute thrombin and ecarin clotting times for
patients on dabigatran
The dilute thrombin and ecarin clotting times (dTT and
ECT) are tests that can be used to measure the anti-
coagulant effect of dabigatran. The activated partial
thromboplastin time (APTT) would also be responsive
to dabigatran, but dose–response is not linear. The PT is
rather unresponsive to dabigatran.
dTT is based on recording the clotting time of a mix-
ture of test plasma and optimal amounts of thrombin.
Dabigatran quenches the activity of thrombin and there-
fore the clotting time prolongation of dTT is propor-
tional to the inhibitory activity of the drug.
ECT is based on the property of the snake venom ecarin
to convert prothrombin into meizothrombin, which can in
turn be measured by recording the prolongation of the
plasma clotting time or by a synthetic chromogenic sub-
strate [16]. Dabigatran quenches meizothrombin and
therefore the clotting time or the chromogenic activity will
be proportional to the activity of dabigatran.
Results for dTT or ECT are usually expressed as clot-
ting time (seconds). They can also be expressed as ratio
(patient-to-normal). Both dTT and ECT proved fairlyresponsive to dabigatran and commercial assays are
available. The clotting times are approximately 2.0- or
3.0-times longer than the baseline value for dTT or
ECT, respectively, when the concentration of dabigatran
is 200 ng/mL [17]. The latter being the plasma concen-
tration that can be found in patients taking 150 mg
dabigatran twice daily. It is, therefore, reasonable to as-
sume that the prolongations of the clotting times
for both tests will be even higher in patients on over-
dosage, that is the situation when testing will probably
be most useful. Cut off values for both tests could be
established in clinical studies to see whether they may
be useful to identify patients at increasing risk of
hemorrhage. However, for these cut off to be used “uni-
versally” (i.e., regardless of the reagent used for testing)
results obtained in different laboratories should be com-
parable. Although the formulation of dTT and ECT is
very simple, it is anticipated that results (even if they are
expressed as ratio) will vary between laboratories. Differ-
ent types (human or bovine) and concentrations of throm-
bin will probably be used by different commercial kits,
which will ultimately make results to vary in different
labs. Standardization of ECT would in principle be
easier since the source of the snake venom (ecarin)
that is used to activate prothrombin comes from the
same source, but application of this test to different
clot detection systems or chromogenic substrates may
introduce some degree of variability.
As mentioned above for rivaroxaban, results of tests
for dabigatran could also be expressed as dabigatran-
equivalent concentrations [18]. This requires provision
of sets of calibration plasmas (that are commercially
available) prepared by spiking a normal plasma with in-
creasing concentrations of the drug. Calibration plasmas
could be tested with local reagents and equipment and
the results used to construct calibration curves. Patients
clotting time or chromogenic activity can in turn be
converted by means of these calibration curves into
dabigatran-equivalent concentrations. Presumably this
system of reporting will experience the same problems
of standardization discussed above for rivaroxaban.
Conclusions
Results of clotting tests can be expressed in different
ways and this was always considered as one of the most
important source of variability to explain the differences
of results obtained for the same patient plasma when
tested in different laboratories. This state of affairs, was
deemed crucial for patient on VKA and led to the devel-
opment of the INR system of results reporting.
Although standardization of results expression for the
tests used to measure the anticoagulant effect of NOA is
presently not perceived as an issue, it may become cru-
cially important at the time when test-specific cut off
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bleeding in individual patients who are on over-dosage.
Effort should, therefore, be made to harmonize as much
as possible results obtained in different laboratories
using the same method, but different reagents.
Whether results of coagulation tests should eventually
be expressed as (standardized) ratio (patient-to-normal)
or as drug concentration-equivalent, interpolated from a
dose–response curve constructed by testing normal
plasmas added with increasing amounts of any of the
NOA, is still a matter of debate and should be explored
by appropriate clinical studies.
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